Special report: current and evolving strategies in the treatment of age-related macular degeneration

BlueCross BlueShield Association

Record Status
This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database.

The BlueCross BlueShield Association Technology Evaluation Center website (www.bcbs.com/tec) includes the most recent 3 years of TEC Assessments. To request older reports, please use the “contact us” feature on the website.

Citation

Authors' objectives
This special report aims to provide an understanding of emerging therapies in the context of: 1) contemporary treatment options and 2) the underpinnings on which age-related macular degeneration (AMD) treatments are based.

Authors' conclusions
Deciphering at least part of the underlying pathophysiology of AMD has brought therapies into the realm of angiostatic agents. Yet as technologies improve our understanding and provide additional treatments for AMD, more broadly portraying the impact of therapies on participants' lives in clinical trials could enable patients and providers to better assess therapeutic efficacy.

Project page URL
http://www.bcbs.com/blueresources/tec/contact-tec.html

Indexing Status
Subject indexing assigned by CRD

MeSH
Antioxidants /therapeutic use; Laser Coagulation; Macular Degeneration /therapy; Photochemotherapy; Vascular Endothelial Growth Factor A /therapeutic use

Language Published
English

Country of organisation
United States

Address for correspondence
BlueCross BlueShield Association, Technology Evaluation Center, 225 North Michigan Ave, Chicago, Illinois, USA. Tel: 888 832 4321 Email: tec@bcbsa.com

AccessionNumber
32006000035

Date bibliographic record published